Editor-in-Chief:
Ivana Cacciatore
Department of Pharmacy
University "G. d'Annunzio" of Chieti-Pescara
Chieti Scalo
Italy
Frequency: Monthly
Submission to final decision: 90-200 days
ISSN (Print):1570-1808
ISSN (Online):1875-628X
HOME
This is a temporarily open system that will be closed on February 20, 2025, and all review processes will follow the previous review standards (https://www.benthamscience.com), during the peer review process, strict adherence to peer review standards will be followed, and once accepted, the manuscript will be submitted to KeAi Publishing House for publication (The journal homepage is under construction).
The Letters in Drug Design & Discovery manuscript submission system is currently being upgraded. The new system will be Elsevier's EM system, which is scheduled to be officially launched on February 18, 2025. Until then, the OJS submission system will be used temporarily, and manuscripts submitted through this system will undergo double-blind peer review, just like formally submitted manuscripts.
It should be noted that manuscripts submitted to this system will be published in an open access manner.
This is a temporary submission system that has been put into use. If you have any questions about submission, please contact the editorial office: lddd@international-life-sciences.com
Letters in Drug Design & Discovery is one of the pharmaceutical series journals under KeAi Publishing, which is responsible for our journal's publication. Our journal will use the Elsevier's Editorial Manager (EM) submission system, but during the set up of the EM system, the Open Journal Systems (OJS) system is temporarily being used for submissions.
Elsevier publishes over 2,500 digital journals, including The Lancet and Cell, as well as 39,000 e-books and many iconic reference works. KeAi Publishing currently has more than 200 journals, and it was jointly established by two world's leading STM publishers—China Science Publishing & Media and Elsevier. It is a unique joint venture in the international publishing industry. KeAi Publishing, based in Beijing, publishes first-class research results that benefit global society. The official website of KeAi Publishing is https://www.keaipublishing.com/en/.
About the submission system: This is a temporary submission system. During the set up of the new system, Letters in Drug Design & Discovery will use the OJS system as an interim solution. Once Elsevier successfully builds the EM system for our journal, all manuscripts submitted during this period will be transferred to Elsevier's EM system and published by KeAi Publishing.
Letters in Drug Design & Discovery publishes Original Article, Review article, Editorial, Clinical Guideline, Letters in all areas of rational drug design and discovery including medicinal chemistry, in-silico drug design, combinatorial chemistry, high-throughput screening, drug targets, and structure-activity relationships. The emphasis is on publishing quality papers very rapidly by taking full advantage of the latest Internet technology for both the submission and review of manuscripts. The journal is an essential reading to all pharmaceutical scientists involved in research in drug design and discovery.
